figure
posted on 2024-02-12, 14:20 authored by Ignacio Campillo-Marcos, Marta Casado-Pelaez, Veronica Davalos, Gerardo Ferrer, Caterina Mata, Elisabetta Mereu, Gael Roué, David Valcárcel, Antonieta Molero, Lurdes Zamora, Blanca Xicoy, Laura Palomo, Pamela Acha, Ana Manzanares, Magnus Tobiasson, Eva Hellström-Lindberg, Francesc Solé, Manel Esteller Distribution of mutant cells within the BM compartments defined by the immunophenotype. A, Percentage of mutant progenitor, immature erythroid and myeloid cells (Pro_Ery_Mye) compared with mutant lymphoid cells in each patient at diagnosis (top); percentage of mutant progenitor, immature erythroid and myeloid (bottom, left); or T, B, and NK cells (bottom, right) in each patient at diagnosis. B, UMAP of BM cells from all samples colored by number of mutations per cell (left); cell type proportions according to the number of mutations per cell (right). C, UMAP colored according to gene mutational status. WT, wild-type; MUT, mutant.
Funding
Government of Catalonia | Departament d'Empresa i Coneixement, Generalitat de Catalunya (Ministry of Business and Knowledge, Government of Catalonia)
Ministerio de Ciencia e Innovación (MCIN)
Fundación Cellex (Cellex Foundation)
Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona (“la Caixa” Foundation)
Fundación Científica Asociación Española Contra el Cáncer (AECC)
EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA)
History
ARTICLE ABSTRACT
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMA), such as azacitidine, have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia. However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we have leveraged the unprecedented analytic power of single-cell technologies to simultaneously map the genome and immunoproteome of MDS samples throughout clinical evolution. We were able to chart the architecture and evolution of molecular clones in precious paired bone marrow MDS samples at diagnosis and posttreatment to show that a combined imbalance of specific cell lineages with diverse mutational profiles is associated with the clinical response of patients with MDS to hypomethylating therapy.
MDS are myeloid clonal hemopathies with a low 5-year survival rate, and approximately half of the cases do not respond to standard HMA therapy. Our innovative single-cell multiomics approach offers valuable biological insights and potential biomarkers associated with the demethylating agent efficacy. It also identifies vulnerabilities that can be targeted using personalized combinations of small drugs and antibodies.
